Sin Gon Kim Korea University, Korea | SS1 The ideal partner for improving at least six pathophysiologic disturbances of T2DM |
Sung Hoon Yu Korea Hanyang University, Korea | SS2 Clinically beneficial effects of lorcaserin in patients with T2DM |
In-Kyung Jeong Kyung Hee University, Korea | BS1 Next generation basal insulin: translating clinical trials into a real-world evidence |
Hye Soon Kim Keimyung University, Korea | BS2 The latest scientific evidence for dipeptidyl peptidase-4 inhibitors with a focus on sitagliptin |
Soo Lim Seoul National University, Korea | LS1 Therapeutic efficacy and safety of initial triple combination of metformin, sitagliptin and lobeglitazone in drug-naive patients with type 2 diabetes |
Eun Gyoung Hong Hallym University, Korea | LS2 The multiple benefits of ipragliflozin beyond glycemic control |
Yong Ho Lee Yonsei University, Korea | LS3 Empagliflozin: how will new evidence inform future clinical care? |
Sung Hee Choi Seoul National University, Korea | LS4 Effects of advanced DPP-4i focused on teneligliptin in patients with renal impairment |
Hyuk Sang Kwon The Catholic University of Korea, Korea | BS3 Insulin degludec/insulin aspart: an innovation-driven combination for diabetes care |
Chang Hee Jung University of Ulsan, Korea | BS4 Scientific journey of linagliptin, a DPP-4inhibitor, over 5years |
Kausik Kumar Ray Imperial College London, UK | LS5 Not all statins are the same: some guidance on how to manage high-risk patients |
Kyung Mook Choi Korea University, Korea | LS6 Diabetes and heart failure : novel data of sacubitril/valsartan & vildagliptin |
Sang Yong Kim Chosun University, Korea | LS7 A novel and simple treatment option for dyslipidemia in T2DM: balance study |